Skip to content

Lifecore Biomedical, Inc. LFCR Finance Lease Liability Payment Due

Finance Lease Liability Payment Due at other companies

BioCryst Pharmaceuticals logo
BioCryst PharmaceuticalsBCRX
$2.67M-42.5%
West Pharmaceutical Services logo
West Pharmaceutical ServicesWST

Other financials

Income statement

See full
Revenue$23.2M-36.4%
Gross profit$4.5M-68.1%
Operating income-$4.7M
Net income-$15.0M-1,206%
EPS (diluted)-$0.43-1,333%

Balance sheet

See full
Cash & equivalents$20.8M+152%
Total debt$156.9M+1,310%
Total equity-$28.4M-2,229%
Total assets$225.5M-5.8%

Cash flow

See full
Operating cash flow$4.7M
CapEx$1.1M-46.7%
Free cash flow$3.6M

Valuation

See full
Market cap$196.92M-35.4%
Enterprise value$333.06M+8.3%
P/S1.6×+0.5×

Profitability

See full
Gross margin31.3%-1.4pp
Operating margin-14.5%-2.2pp
Net margin-30%
FCF margin-36.4%

Returns & leverage

See full
Return on equity-612.1%
Debt / equity8.3×-1.5×
Current ratio3.8×+0.9×

Where this comes from

Reported directly by Lifecore Biomedical, Inc. in its filing.

Tagged under the XBRL concept us-gaap:FinanceLeaseLiabilityPaymentsDue.

The official record: Lifecore Biomedical, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Lifecore Biomedical, Inc.'s finance lease liability payment due.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Lifecore Biomedical, Inc.'s finance lease liability payment due?
Lifecore Biomedical, Inc. (LFCR) reported finance lease liability payment due of $9.38M in Q1 2026.
What does finance lease liability payment due mean?
This represents the total future cash payments required to satisfy finance lease obligations. Unlike operating leases, finance leases are treated similarly to debt-financed asset acquisitions. This metric is crucial for understanding the company's total debt-like obligations and capital structure.